质子泵抑制剂联合胃动力药治疗咽喉反流性疾病临床分析  

The clinical analysis of proton pump inhibitor combined with gastroprokinetic agents in the treatment laryngopharyngeal reflux disease

作　　者：成雷[1] 孙凤新[1] 王涛[1] 李凤 

机构地区：[1]北京市大兴区人民医院耳鼻咽喉头颈外科,北京102600

出　　处：《中国医学文摘（耳鼻咽喉科学）》2017年第6期339-341,共3页Chinese Medical Digest(Otorhinolaryngology)

摘　　要：目的通过埃索美拉唑联合莫沙必利诊断性治疗咽喉反流性疾病(Laryngopharyngeal reflux disease,LPRD),观察治疗前后反流症状和体征的变化情况。方法将疑似LPRD的54例患者诊断性埃索美拉唑联合莫沙必利治疗8周,治疗前后均行反流症状指数评分量表(reflux symptom index,RSI)和反流体征评分量表(reflux finding score,RFS)评分,统计分析用药前后RSI和RFS评分。结果 54例疑似LPRD患者给予埃索美拉唑联合莫沙必利诊断性治疗,治疗前后RSI总分差异有统计学意义(t=16.35,P<0.001),治疗前后RFS总分差异有统计学意义(t=15.55,P<0.001)。结论质子泵抑制剂联合胃动力药治疗LPRD,患者症状和体征改善明显。Objective To observe the effect of esomeprazole combined with mosapride in the treatment of Laryngopharyngeal reflux disease（LPRD）after evaluation of the changes of symptoms and signs before and after treatment. Methods 54 patients who were diagnosed as suspected LPRD were given diagnostic treatment with esomeprazole combined with mosapride for 8 weeks. Reflux finding score（RFS） and reflux symptoms index（RSI）score were evaluated before and after treatment. RSI and RFS were statistical analyzed. Results After diagnostic treatment with esomeprazole combined with mosapride,the RSI score had statistically significant difference（t=16.35,P〈0.001）,as well as the RSI score（t=15.55,P〈0.001）. Conclusion Proton pump inhibitor（PPI）combined with gastroprokinetic agents can significantly improved the symptoms and signs of LPRD.

关 键 词：咽喉反流性疾病 体征和症状 质子泵抑制剂 

分 类 号：R650.5[医药卫生—外科学]